Drug Approval | March 01, 2022
Lupin launches Sevelamer Hydrochloride tablets in the United States
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
Subscribe To Our Newsletter & Stay Updated
